Reported 1 day ago
Redburn Atlantic has reaffirmed its 'Buy' rating on Gilead Sciences, Inc. (NASDAQ:GILD) and set a price target of $143. This follows Gilead's recent achievement of marketing authorization for its twice-yearly injectable HIV-1 treatment, Yeytuo, in the European Union. As a leading biotech company, Gilead focuses on serious diseases and operates in over 35 countries, though some analysts suggest alternative investments may offer greater potential.
Source: YAHOO